Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples

Abstract

The expression of CD161 was closely related to the pathology and molecular pathology of glioma. Meanwhile, CD161 promoted the progression and evolution of gliomas through its unique effect on T cell dysfunction. Thus, CD161 is a promising novel target for immunotherapeutic strategies in glioma treatment.